Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Molecular and genetic determinants of response to PD-1 blockade in recurrent glioblastoma patients.
Electronic Poster Presenter(s)
Robert M. Prins
Professor
University of California Los Angeles
Los Angeles, California
https://eventscribe.com/2020/SNO/fsPopup.asp?Mode=posterinfo&PosterID=318907
Sentiment,
I replied to Laura Pioppo (EMA) to thank her and I also noted that the GB trial has been updated again.
Anders,
Thanks!
I got a reply from Laura Pioppo (EMA ).
See post: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158983706
From my experience I can confirm that Laura Pioppo is always very helpful in clarifying a problem related to clinical trials in general. I know her from a presentation given during the event:
Clinical trials in the EU - How European Reference Networks can add value to clinical research.
sentiment,
here it is;
part of my email
My query:
Can you tell me why there is a difference in the description of the endpoints of this clinical trial in German version compared to GB version.
Could it have to do with not updating the clinical trial status in time?
reply 1h30m ago,
Yes, it's new. I sent an email to the EMA this morning asking them why there is a difference between the UK and German version of the status of the trial. I haven't received a reply yet but it looks like they are updating the trial status.
anders2211,
Thank you for the phone call and thanks for sharing this info!
Thursday, I sent an email to PEI (Paul-Ehrlich-Institut) and asked them why those changes are not reflected yet on the German site.
I'm waiting for a reply.
CaptainOblivious,
Yes, LTBK-01 and LTBK-04 presentation are of similar lenght.
ATLnsider,
Wow, thank you!
Today the German version has not yet been adjusted but I expect an adjustment one of the following days.
exwannabe,
honestly, I think they know that!
abc1212,
Thank you!
I want to add this quote from Lord David Prior, chair of NHS England (May 2, 2019)
Is Les Goldman wearing a wig?
Evaluate,
Thank you!
Sojourner55,
Thank you!
Is there a link to these pictures? (except the other forum)
Edit:
Pay attention to the little flags on the table!
Dr. Bala,
Thank you for posting the Linda Powers talk video!!! Much appreciated!
sentiment,
Thank you!!! And yes, great to hear that they are still on track for top line data in September.
FLASKWORKS LLC TRADEMARKS
There are 8 trademarks either applied for or owned by companies that go by the name of Flaskworks LLC.
The trademarks on file for companies that go by the name of Flaskworks LLC are Baton, Eden, Flask Works, Flaskworks, and Microden.
https://www.bizapedia.com/trademarks/owners/flaskworks-llc.html
EDEN TRADEMARK INFORMATION
FLASKWORKS, LLC
Updated August 14, 2020
https://www.bizapedia.com/trademarks/eden-88182005.html
CODE: GS0051
DESCRIPTION:
Cell Culture Systems For Producing Dendritic Cells, Namely, Cell Culture Media For Cultivating Human Dendritic Cells
Pattyloco,
I posted this July 27,2020
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157187293
Flipper44,
I agree. Same thought. I'll probably know more about the "halt" in two weeks.
Flipper44,
I found a Consultation Document from 2018:
“Good Clinical Practice for Advanced Therapy Medicinal Products”
https://ec.europa.eu/health/sites/health/files/files/advtherapies/2018_gcp_atmp_en.pdf
Here is the quote from 2018:
Sorry, I posted the draft, here's the final version:
Brussels, 10.10.2019 C(2019) 7140 final
https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-10/atmp_guidelines_en.pdf
same quote:
EUROPEAN COMMISSION
Brussels, XXX […](2019) XXX draft
GUIDELINES
on Good Clinical Practice for Advanced Therapy Medicinal Products
https://ec.europa.eu/health/sites/health/files/files/committee/pharm772_gcp_guidelines_annex_en.pdf